Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes

TP53 mutations are associated with adverse outcomes and shorter response to hypomethylating agents (HMAs) in myelodysplastic syndrome (MDS). Limited data have evaluated the impact of the type, number, and patterns of TP53 mutations in response outcomes and prognosis of MDS. We evaluated the clinicop...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Blood Adv
Autori principali: Montalban-Bravo, Guillermo, Kanagal-Shamanna, Rashmi, Benton, Christopher B., Class, Caleb A., Chien, Kelly S., Sasaki, Koji, Naqvi, Kiran, Alvarado, Yesid, Kadia, Tapan M., Ravandi, Farhad, Daver, Naval, Takahashi, Koichi, Jabbour, Elias, Borthakur, Gautham, Pemmaraju, Naveen, Konopleva, Marina, Soltysiak, Kelly A., Pierce, Sherry R., Bueso-Ramos, Carlos E., Patel, Keyur P., Kantarjian, Hagop, Garcia-Manero, Guillermo
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2020
Soggetti:
Myeloid Neoplasia
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7013259/
https://ncbi.nlm.nih.gov/pubmed/32027746
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001101
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi